GILEAD SCIENCES INC

Gilead’s modest market gains come as it expands the long‑acting HIV‑prevention drug lenacapavir, partnering with GFATM to reach millions of high‑risk people worldwide.

Gilead Sciences’ $200‑$250 M purchase of Tubulis expands its ADC portfolio, secures patent protection, and boosts oncology revenue with a 23 % IRR.

Gilead’s $2.2 B acquisition of Ouro Medicines expands its portfolio into high‑growth autoimmune disease therapy, promising diversified revenue, stronger R&D and above‑average ROIC.

Explore how Gilead Sciences’ AI‑driven R&D and high‑impact therapies drive growth, investor confidence, and market positioning in biotech.

Gilead’s Phase 3 ARTISTRY results show a single‑tablet bictegravir/lenacapavir combo keeping HIV suppressed, positioning it for long‑acting therapy, market access, and strategic growth.

Gilead Sciences bolsters investor confidence by attending key healthcare conferences and plans to acquire oncology firm Arcellx, using cash and a contingent value right to diversify revenue, strengthen its ADC portfolio, and hedge against patent cli…

Institutional investors split on Gilead Sciences: European and Canadian funds buy while US large‑cap funds sell, reflecting differing views on patent cliffs, pipeline growth, and strategic M&A.

Investors shift on Gilead Sciences: margin erosion, regulatory heads‑wind and ESG risk explain the net outflow, while new drugs and digital health offer hidden upside.

Institutional buying and analyst upgrades highlight Gilead Sciences as a defensive, high‑margin biopharma with a robust oncology pipeline, but patent expirations and regulatory risks remain key considerations.

Gilead’s Trodelvy + Keytruda combo shows a 32% OS boost for metastatic triple‑negative breast cancer, but with higher toxicity—what it means for investors, regulators, and payers.